Sources

[←1]

^{Fernández-Ruiz, J., et al.. “Endocannabinoids and Neurodegenerative Disorders: Parkinson’s Disease, Huntington’s Chorea, Alzheimer’s Disease, and Others.” Endocannabinoids. Springer International Publishing, 2015. 233-259.}

[←2]

^{Fernández-Ruiz, J., et al. “Neurodegenerative disorders other than multiple sclerosis.” Handbook of cannabis, Oxford University Press, Oxford (2014): 505-525.}

[←3]

^{Sagredo, Onintza, et al. “Cannabinoids: novel medicines for the treatment of Huntington's disease.” Recent patents on CNS drug discovery 7.1 (2012): 41-48.}

[←4]

^{Sagredo, Onintza, et al. “Neuroprotective effects of phytocannabinoid‐based medicines in experimental models of Huntington's disease.” Journal of neuroscience research 89.9 (2011): 1509-1518.}

[←5]

^{Curtis A, Rickards H. Nabilone could treat chorea and irritability in Huntington's disease. Neuropsychiatry Clin Neurosci 2006; 18:553-4.}

[←6]

^{Curtis A, Mitchell I, Patel S, Ives N, Rickards H. A pilot study using nabilone for symptomatic treatment in Huntington's disease. Mov Disord 2009; 24: 2254-9.}

[←7]

^{Müller-Vahl KR, Schneider U, Emrich HM. Nabilone increases choreatic movements in Huntington's disease. Mov Disord 1999;14: 1038-40.}